Clearpoint Neuro (CLPT) investor relations material

Company overview and business model

• Commercial-stage medical device company focused on minimally invasive neurosurgical platforms and biologics partnerships.

• Core product is the ClearPoint Navigation System, used globally for MRI-guided and operating room neurosurgery procedures.

• Expanded product line includes SmartFrame Array, SmartFrame OR Stereotactic System, and ClearPoint Prism Neuro Laser Therapy System.

• Biologics and drug delivery partnerships support preclinical and clinical studies for direct brain therapy delivery, with over 60 customers.

• Growth in biologics depends on customer relationships, clinical trial success, regulatory approvals, and therapy commercialization.

Financial performance and metrics

• Classified as a "smaller reporting company" with less than $700 million in public float and under $100 million in annual revenue for the most recent fiscal year.

• May continue to use scaled disclosure and reduced reporting requirements as long as thresholds are not exceeded.

Use of proceeds and capital allocation

• Will not receive any proceeds from the resale of shares by selling stockholders; all proceeds go to the selling stockholders.